BIOTHERIS, Department of Interventional Radiology, Gustave Roussy, Université Paris-Saclay, 114 rue Edouard Vaillant, 94805, Villejuif, France.
Department of Radiology, St-Eloi University Hospital, Montpellier, France.
Cardiovasc Intervent Radiol. 2022 Nov;45(11):1701-1709. doi: 10.1007/s00270-022-03267-z. Epub 2022 Sep 20.
To assess the feasibility and safety of a robotic system for percutaneous needle insertion during thermal ablation of liver tumors.
This study analyzed the CT-guided percutaneous needle insertion using the EPIONE robotic device (Quantum Surgical, Montpellier, France) for radiofrequency or microwave liver ablation. The main criteria of the study were feasibility (possibility to perform the thermal ablation after needle insertion), the number of needle adjustments (reiteration of robotically assisted needle insertion when initial needle positioning is considered insufficient to perform ablation), and robotic-guided procedure safety (complications related to the needle insertion). Patients were followed up at 6 months post-intervention to assess local tumor control.
Twenty-one patients with 24 tumors, including 6 HCC and 18 metastases measuring 15.6 ± 7.2 mm, were enrolled. One patient (with one tumor) was excluded for protocol deviation. Robotic assisted thermal ablation was feasible for 22/23 lesions (95.7%) and 19/20 patients (95.0%), as validated by a data safety monitoring Board (95% CI [76.39%; 99.11%]) for the per-protocol population. The mean number of needle adjustments per tumor treated was 0.4 (SD: 0.7), with 70.8% of tumors requiring no adjustment. No adverse events were depicted. Rate of local tumor control was 83.3% for patients and 85.7% for tumors, at 6 months.
This bicentric first-in-human pilot study suggests both feasibility and safety of a stereotactic CT-guided EPIONE device for the percutaneous needle insertion during liver tumor thermal ablation.
评估一种用于肝肿瘤热消融的机器人系统进行经皮穿刺针插入的可行性和安全性。
本研究分析了使用 EPIONE 机器人设备(法国蒙彼利埃的 Quantum Surgical)进行 CT 引导的经皮穿刺针插入,用于射频或微波肝消融。该研究的主要标准是可行性(在插入针后进行热消融的可能性)、针调整次数(当初始针定位被认为不足以进行消融时,重复机器人辅助针插入)以及机器人引导程序的安全性(与针插入相关的并发症)。患者在干预后 6 个月进行随访,以评估局部肿瘤控制情况。
共纳入 21 例 24 个肿瘤患者,其中包括 6 例 HCC 和 18 例转移瘤,大小为 15.6±7.2mm。因违反方案,1 例患者(1 个肿瘤)被排除。机器人辅助热消融在 22/23 个病灶(95.7%)和 19/20 名患者(95.0%)中是可行的,这一结果得到了数据安全监测委员会的验证(意向治疗人群的 95%CI[76.39%;99.11%])。每个治疗肿瘤的平均针调整次数为 0.4(SD:0.7),其中 70.8%的肿瘤无需调整。未出现不良事件。6 个月时患者和肿瘤的局部肿瘤控制率分别为 83.3%和 85.7%。
这项在人类中的首次使用 EPIONE 设备的立体定向 CT 引导经皮穿刺针插入的前瞻性、单臂、多中心的可行性和安全性研究,为肝肿瘤热消融提供了一种新的选择。